Rapport Therapeutics (RAPP) Competitors $16.05 -0.57 (-3.43%) Closing price 04:00 PM EasternExtended Trading$16.09 +0.04 (+0.25%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RAPP vs. DNLI, BEAM, KNSA, BLTE, CNTA, VCEL, IRON, HRMY, IDYA, and CGONShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Kiniksa Pharmaceuticals International (KNSA), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), Disc Medicine (IRON), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Its Competitors Denali Therapeutics Beam Therapeutics Kiniksa Pharmaceuticals International Belite Bio Centessa Pharmaceuticals Vericel Disc Medicine Harmony Biosciences IDEAYA Biosciences CG Oncology Rapport Therapeutics (NASDAQ:RAPP) and Denali Therapeutics (NASDAQ:DNLI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability. Is RAPP or DNLI more profitable? Rapport Therapeutics' return on equity of -25.48% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rapport TherapeuticsN/A -25.48% -24.63% Denali Therapeutics N/A -35.90%-32.41% Which has stronger valuation and earnings, RAPP or DNLI? Denali Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapport TherapeuticsN/AN/A-$78.31M-$3.45-4.65Denali TherapeuticsN/AN/A-$422.77M-$2.67-5.12 Does the media favor RAPP or DNLI? In the previous week, Denali Therapeutics had 3 more articles in the media than Rapport Therapeutics. MarketBeat recorded 4 mentions for Denali Therapeutics and 1 mentions for Rapport Therapeutics. Denali Therapeutics' average media sentiment score of 1.63 beat Rapport Therapeutics' score of 0.94 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Rapport Therapeutics Positive Denali Therapeutics Very Positive Do institutionals and insiders have more ownership in RAPP or DNLI? 92.9% of Denali Therapeutics shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend RAPP or DNLI? Rapport Therapeutics currently has a consensus target price of $28.00, suggesting a potential upside of 74.45%. Denali Therapeutics has a consensus target price of $33.71, suggesting a potential upside of 146.63%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than Rapport Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.06 SummaryDenali Therapeutics beats Rapport Therapeutics on 9 of the 13 factors compared between the two stocks. Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$585.83M$3.04B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-4.6521.1828.1120.03Price / SalesN/A337.65460.63103.88Price / CashN/A43.2336.5559.01Price / Book1.928.368.655.90Net Income-$78.31M-$55.19M$3.25B$258.66M7 Day Performance9.33%5.89%4.20%2.23%1 Month Performance36.83%17.63%10.83%12.77%1 Year Performance-27.74%5.10%34.67%19.36% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPPRapport Therapeutics1.5018 of 5 stars$16.05-3.4%$28.00+74.5%-17.8%$585.83MN/A-4.65N/ADNLIDenali Therapeutics4.2552 of 5 stars$14.69+1.2%$33.71+129.5%-39.4%$2.13B$330.53M-5.50430News CoveragePositive NewsUpcoming EarningsBEAMBeam Therapeutics2.2175 of 5 stars$21.17+0.0%$48.75+130.3%-29.7%$2.13B$63.52M-4.59510Analyst RevisionKNSAKiniksa Pharmaceuticals International3.4535 of 5 stars$28.80+2.5%$39.33+36.6%+6.7%$2.10B$423.24M-115.20220News CoverageBLTEBelite Bio1.7942 of 5 stars$63.58+0.6%$96.67+52.0%+28.5%$2.02BN/A-46.7510High Trading VolumeCNTACentessa Pharmaceuticals3.3153 of 5 stars$15.13+4.9%$27.89+84.3%+51.2%$2.02B$15M-8.36200High Trading VolumeVCELVericel3.6708 of 5 stars$39.82-0.3%$61.14+53.5%-24.2%$2.00B$238.54M1,327.78300News CoveragePositive NewsUpcoming EarningsIRONDisc Medicine3.3594 of 5 stars$57.74+1.5%$96.70+67.5%+36.0%$2.00BN/A-14.7330HRMYHarmony Biosciences4.7967 of 5 stars$34.71+2.1%$51.33+47.9%+11.9%$1.99B$714.73M13.25200Positive NewsAnalyst RevisionIDYAIDEAYA Biosciences4.1856 of 5 stars$22.58+0.4%$47.55+110.6%-41.2%$1.98B$7M-6.2980News CoverageAnalyst ForecastCGONCG Oncology2.236 of 5 stars$25.90-3.1%$56.80+119.3%-21.3%$1.97B$1.14M-17.1561 Related Companies and Tools Related Companies DNLI Competitors BEAM Competitors KNSA Competitors BLTE Competitors CNTA Competitors VCEL Competitors IRON Competitors HRMY Competitors IDYA Competitors CGON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPP) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RAPP Stock Alerts